{"pub": "investing.com", "url": "https://au.investing.com/news/stock-market-news/briefmithra-signs-landmark-contract-for-estelle-with-mayne-pharma-1966503", "downloaded_at": "2019-10-01 12:46:15.742809+00:00", "title": "BRIEF-Mithra Signs Landmark Contract For Estelle\u00ae With Mayne Pharma", "language": "en", "text": "BRIEF-Mithra Signs Landmark Contract For Estelle\u00ae With Mayne Pharma\n\nStock Markets 16 minutes ago (Oct 01, 2019 22:30)\n\n\u00a9 Reuters. BRIEF-Mithra Signs Landmark Contract For Estelle\u00ae With Mayne Pharma Oct 1 (Reuters) - MITHRA PHARMACEUTICALS SA : * MITHRA SIGNS LANDMARK CONTRACT FOR ESTELLE\u00ae IN THE UNITED STATES WITH MAYNE PHARMA * MITHRA ELIGIBLE FOR LICENSE FEES OF AT LEAST USD 295 MILLION * MITHRA TO BE AWARDED 9.6% EQUITY STAKE ACROSS TWO TRANCHES IN MAYNE PHARMA * POTENTIAL GROSS REVENUES IN MITHRA'S WORST-CASE SCENARIO AT A MINIMUM OF EUR 4,5 BILLION, WHICH REPRESENTS MORE THAN TWICE SIZE OF EUROPEAN DEAL * CDMO CROSS FERTILIZATION OPPORTUNITIES FOR BOTH COMPANIES * PARTIES WILL WORK TOGETHER ON REGULATORY SUBMISSION PLANNED BY END 2019 WITH PROJECTED COMMERCIAL LAUNCH OF ESTELLE\u00ae IN H1 2021\n\nBRIEF-Mithra Signs Landmark Contract For Estelle\u00ae With Mayne Pharma", "description": "BRIEF-Mithra Signs Landmark Contract For Estelle\u00ae With Mayne Pharma", "authors": [], "top_image": "https://i-invdn-com.akamaized.net/news/LYNXNPEB65083_L.jpg", "published_at": "2019-10-01"}